Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
2011 ◽
Vol 29
(15_suppl)
◽
pp. 5561-5561
◽
Keyword(s):
Phase Ii
◽